Logo image of APVO

APTEVO THERAPEUTICS INC (APVO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:APVO - US03835L5049 - Common Stock

1.34 USD
-0.01 (-0.74%)
Last: 12/8/2025, 8:00:00 PM
1.3 USD
-0.04 (-2.99%)
After Hours: 12/8/2025, 8:00:00 PM
Fundamental Rating

2

Overall APVO gets a fundamental rating of 2 out of 10. We evaluated APVO against 531 industry peers in the Biotechnology industry. The financial health of APVO is average, but there are quite some concerns on its profitability. APVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APVO had negative earnings in the past year.
APVO had a negative operating cash flow in the past year.
In the past 5 years APVO reported 4 times negative net income.
In the past 5 years APVO always reported negative operating cash flow.
APVO Yearly Net Income VS EBIT VS OCF VS FCFAPVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

APVO's Return On Assets of -103.54% is on the low side compared to the rest of the industry. APVO is outperformed by 77.02% of its industry peers.
APVO's Return On Equity of -160.72% is on the low side compared to the rest of the industry. APVO is outperformed by 66.29% of its industry peers.
Industry RankSector Rank
ROA -103.54%
ROE -160.72%
ROIC N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
APVO Yearly ROA, ROE, ROICAPVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APVO Yearly Profit, Operating, Gross MarginsAPVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for APVO has been increased compared to 1 year ago.
The number of shares outstanding for APVO has been increased compared to 5 years ago.
APVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APVO Yearly Shares OutstandingAPVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500 1K 1.5K
APVO Yearly Total Debt VS Total AssetsAPVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

APVO has an Altman-Z score of -15.05. This is a bad value and indicates that APVO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -15.05, APVO is not doing good in the industry: 80.79% of the companies in the same industry are doing better.
There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.05
ROIC/WACCN/A
WACCN/A
APVO Yearly LT Debt VS Equity VS FCFAPVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

APVO has a Current Ratio of 4.03. This indicates that APVO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.03, APVO is in line with its industry, outperforming 47.65% of the companies in the same industry.
APVO has a Quick Ratio of 4.03. This indicates that APVO is financially healthy and has no problem in meeting its short term obligations.
APVO has a Quick ratio (4.03) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.03
Quick Ratio 4.03
APVO Yearly Current Assets VS Current LiabilitesAPVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

APVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.08%, which is quite impressive.
EPS 1Y (TTM)87.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, APVO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.95%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APVO Yearly Revenue VS EstimatesAPVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2029 2030 2031 2032 50M 100M 150M
APVO Yearly EPS VS EstimatesAPVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500K -1M -1.5M -2M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APVO. In the last year negative earnings were reported.
Also next year APVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APVO Price Earnings VS Forward Price EarningsAPVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APVO Per share dataAPVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K

4.3 Compensation for Growth

APVO's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

APVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTEVO THERAPEUTICS INC

NASDAQ:APVO (12/8/2025, 8:00:00 PM)

After market: 1.3 -0.04 (-2.99%)

1.34

-0.01 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-12 2026-02-12/amc
Inst Owners2.95%
Inst Owner Change4091.74%
Ins Owners0.08%
Ins Owner Change2.1%
Market Cap22.58M
Revenue(TTM)N/A
Net Income(TTM)-27.95M
Analysts82.86
Price Target428.4 (31870.15%)
Short Float %4.63%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.43%
Min EPS beat(2)12.75%
Max EPS beat(2)90.1%
EPS beat(4)2
Avg EPS beat(4)-210.34%
Min EPS beat(4)-942%
Max EPS beat(4)90.1%
EPS beat(8)6
Avg EPS beat(8)-73.73%
EPS beat(12)9
Avg EPS beat(12)-32.62%
EPS beat(16)12
Avg EPS beat(16)6.37%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)99.4%
EPS NY rev (1m)62.06%
EPS NY rev (3m)98.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-1745.46
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.55
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS1.03
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -103.54%
ROE -160.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.03
Quick Ratio 4.03
Altman-Z -15.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.48%
EPS Next Y99.95%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-110.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.33%
OCF growth 3YN/A
OCF growth 5YN/A

APTEVO THERAPEUTICS INC / APVO FAQ

What is the ChartMill fundamental rating of APTEVO THERAPEUTICS INC (APVO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to APVO.


What is the valuation status for APVO stock?

ChartMill assigns a valuation rating of 1 / 10 to APTEVO THERAPEUTICS INC (APVO). This can be considered as Overvalued.


How profitable is APTEVO THERAPEUTICS INC (APVO) stock?

APTEVO THERAPEUTICS INC (APVO) has a profitability rating of 0 / 10.


How financially healthy is APTEVO THERAPEUTICS INC?

The financial health rating of APTEVO THERAPEUTICS INC (APVO) is 6 / 10.